Clinical trials: MYOPATHY
Rotator Cuff Tendinitis, Syndrome Rotator Cuff
Performance and Safety Evaluation of MD-Shoulder Collagen Medical Device in the Treatment of Rotator Cuff Syndrome
Rotator Cuff Syndrome is a commonly encountered musculoskeletal disorder in clinical practice, with an incidence ranging from 0.3% to 5.5%, and an annual prevalence of 0.5% to 7.4%.
- Conditions
- Rotator Cuff Tendinitis, Syndrome Rotator Cuff, Tendinopathy, Tendinoses, Rotator Cuff
- Trial name
- ROPIRAMED (NCT05489484)
- Testing
- MD-Shoulder Collagen Medical Device
- Where
- Italy
- Volunteers
- 24 people
- Sponsor
- Guna S.p.a
Musculoskeletal Conditions, Musculoskeletal Pain
Compex SP8.0 - Symptomatic Treatment of Musculoskeletal Pain
This post-market clinical study of the SP8.0 Compex device aims to comprehensively assess the safety and performance of the device when used in accordance with the approved Instructions for Use.
- Trial name
- NCT06717789
- Testing
- Transcutaneous Electrical Nerve Stimulation (TENS) with the Compex SP8.0 device
- Where
- 2 sites in United Kingdom
- Volunteers
- 74 people
- Sponsor
- DJO UK Ltd
Primary Body Region (Arranged Most Common to Least), Lumbar/SI
ATI Evidence-based Guide Investigating Clinical Services
The goal of this study is to evaluate how standard-of-care outpatient rehabilitation is delivered and how variation in care delivery mechanisms relates to clinical outcomes, service utilization, and value in patients receiving…
- Conditions
- Primary Body Region (Arranged Most Common to Least), Lumbar/SI, Knee, Shoulder
- Trial name
- AEGIS (NCT02285868)
- Where
- United States
- Volunteers
- 4,000,000 people, healthy volunteers welcome
- Sponsor
- ATI Holdings, LLC
Fibromyalgia
Pramipexole ER vs. Placebo in Fibromyalgia
The primary objective of this study is to assess the efficacy and safety of an extended-release (ER) formulation of pramipexole in comparison with placebo for the treatment of fibromyalgia.
- Trial name
- NCT00689052
- Testing
- pramipexole ER
- Where
- 42 sites in United States
- Volunteers
- 61 people
- Sponsor
- Boehringer Ingelheim
Duchenne Muscular Dystrophy
Extension Study of NS-065/NCNP-01 in Boys With Duchenne Muscular Dystrophy (DMD)
This is an open-label, extension study of NS-065/NCNP-01 administered intravenously once weekly for an additional 192 weeks to boys with DMD who complete Study NS-065/NCNP-01-201.
- Trial name
- NCT03167255
- Testing
- NS-065/NCNP-01
- Where
- 6 sites in United States, Canada
- Volunteers
- 16 people
- Sponsor
- NS Pharma, Inc.
Thymidine Kinase 2 (TK2)
A RETROspective Study of Patients With TK2d
This is a medical chart review study to collect information for patients who have been taking pyrimidine nucleosides for treatment of TK2 deficiency.
- Trial name
- RETRO (NCT03701568)
- Testing
- dC/dT
- Where
- 8 sites in United States, Israel and 1 more
- Volunteers
- 38 people
- Sponsor
- Zogenix MDS, Inc.
Duchenne Muscular Dystrophy
A Study of TAS-205 for Duchenne Muscular Dystrophy
The objective of this study is to evaluate the safety and pharmacokinetic of TAS-205 in patients with Duchenne Muscular Dystrophy.
- Trial name
- NCT02246478
- Testing
- TAS-205
- Where
- Japan
- Volunteers
- 23 people
- Sponsor
- Taiho Pharmaceutical Co., Ltd.
Muscle Pain
Study of Etoricoxib for the Treatment of Muscle Pain and Inflammation Induced by Eccentric Exercise
Comparison of the effect of etoricoxib to placebo on muscle pain caused by eccentric contractions
- Trial name
- NCT01271348
- Testing
- Etoricoxib
- Where
- Germany
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- X-pert Med GmbH
ANCA-Associated Vasculitis (AAV), Idiopathic Inflammatory Myositis (IIM)
FT839 in Autoimmune Diseases
The primary objectives of this trial are to evaluate the safety and tolerability and to determine the maximum tolerated dose (MTD) or recommended Phase 2 dose of FT839 with or without rituximab and/or background therapy and/or…
- Conditions
- ANCA-Associated Vasculitis (AAV), Idiopathic Inflammatory Myositis (IIM), Rheumatoid Arthritis (RA), Systemic Lupus Erythematosus (SLE)
- Trial name
- NCT07800871
- Testing
- FT839
- Where
- United States
- Volunteers
- 446 people
- Sponsor
- Fate Therapeutics
Duchenne Muscular Dystrophy
NS-050/NCNP-03 in Boys With DMD (Meteor50)
This is a Phase 1/2 study of Multiple-Ascending Dose (MAD) levels for 12 weeks of treatment followed by 24 weeks of open-label treatment with a selected dose of NS-050/NCNP-03 administered once weekly to ambulant boys with DMD…
- Trial name
- NCT06053814
- Testing
- NS-050/NCNP-03
- Where
- 19 sites in United States, Canada and 3 more
- Volunteers
- 20 people
- Sponsor
- NS Pharma, Inc.
Musculoskeletal Pain
Evaluation of Erchonia PPL Laser as a Pretreatment Adjunct to Enhance Standard Erchonia Red Laser for the Relief of Pain
This study is to see if applying pre-treatment with the Erchonia® PPL blue laser therapy, followed sequentially with the standard Erchonia red laser therapy can help reduce nociceptive musculoskeletal pain
- Trial name
- NCT07121933
- Testing
- Erchonia® PPL blue laser therapy, followed sequentially with the standard Erchonia red laser therapy
- Where
- United States
- Volunteers
- 44 people
- Sponsor
- Erchonia Corporation
Stroke, Spasticity
Phase III Study of Botulax® to Treat Post Stroke Upper Limb Spasticity
The purpose of this study is to evaluate the safety and efficacy of Botulax® compared to Botox® reducing upper limb muscle tone in post stroke patients.
- Trial name
- NCT01915459
- Testing
- Botulinum toxin type A(Botulax®), Botulinum toxin type A(Botox®)
- Where
- 6 sites in South Korea
- Volunteers
- 186 people
- Sponsor
- Hugel
Chronic Atypical Neutrophilic Dermatosis With Lipodystrophy and Elevated Temperature (CANDLE), Juvenile Dermatomyositis (JDM)
Compassionate Use Protocol for the Treatment of Autoinflammatory Syndromes
The Requesting Physician/Investigator contacts Lilly when, based on their medical opinion, a patient meets the criteria for inclusion in the expanded access program.
- Conditions
- Chronic Atypical Neutrophilic Dermatosis With Lipodystrophy and Elevated Temperature (CANDLE), Juvenile Dermatomyositis (JDM), Stimulator of Interferon Genes (STING)-Associated Vasculopathy With Onset During Infancy (SAVI), Aicardi-Goutières Syndrome (AGS)
- Trial name
- NCT01724580
- Testing
- Baricitinib
- Where
- 3 sites in United States, United Kingdom
- Sponsor
- Eli Lilly and Company
Stroke Gait Rehabilitation
The Effect of Cupping on Spasticity and Function of the Lower Extremity During Rehabilitation After Stroke
Physical therapists use dry static cupping for the treatment of many conditions, including spasticity for patients post-stroke. While research better describes the effects of dry static cupping for patients with orthopedic…
- Trial name
- NCT06653855
- Testing
- Dry Static Cupping, Standard physical therapy treatment
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Scott Getsoian
Rheumatic Diseases, Arthralgia
PASCOE-Agil HOM-Injektopas in the Treatment of Rheumatic Disorders
The purpose of this observational study is to give an overview of the use of PASCOE-Agil HOM-Injektopas in a 2-4 week treatment of rheumatic disorders.
- Conditions
- Rheumatic Diseases, Arthralgia, Myalgias/Myopathy, Lumbago
- Trial name
- 157 (NCT00922428)
- Volunteers
- 1,389 people
- Sponsor
- Pascoe Pharmazeutische Praeparate GmbH
Myotonic Dystrophy Type 1
Safety and Efficacy Study of Recombinant Human Insulin-Like Growth Factor-I/Recombinant Human Insulin-Like Growth Factor Binding Protein-3 (rhIGF-I/rhIGFBP-3) In Myotonic Dystrophy Type 1
To investigate the effects of rhIGF-I/rhIGFBP-3 treatment for 24 weeks on endurance, ambulation, cognitive functioning, insulin resistance, lipid levels, muscle function and strength, pain, gastrointestinal functioning, and…
- Trial name
- NCT00577577
- Testing
- rhIGF-I/rhIGFBP-3
- Where
- 12 sites in United States
- Volunteers
- 69 people
- Sponsor
- Insmed Incorporated
Duchenne Muscular Dystrophy
NSAA NON-Interventional Study Protocol
The purpose of this non-interventional study is to evaluate the feasibility of remotely administering the North Star Ambulatory Assessment (NSAA) to participants with Duchenne muscular dystrophy (DMD).
- Trial name
- NCT06054971
- Testing
- Remote Administration of NSAA
- Where
- United States
- Volunteers
- 31 people
- Sponsor
- Red Nucleus Enterprise Solutions, LLC
Primary Fibromyalgia
12-Month Open-Label Long-term Safety Study of TNX-102 SL Tablets in Fibromyalgia Patients
This was an open-label, extension trial designed to evaluate the long-term safety over 12 months of TNX-102 SL tablets taken daily at bedtime for the treatment of fibromyalgia.
- Trial name
- BESTFIT-OLE (NCT02015234)
- Testing
- TNX-102 SL
- Where
- 13 sites in United States
- Volunteers
- 158 people
- Sponsor
- Tonix Pharmaceuticals, Inc.
Muscle Soreness
Multiple Dose, Double-Blind, Placebo and Active Controlled Study of Pharmacokinetics of Diractin® as Well as Safety and Efficacy for the Treatment of Muscle Soreness
Multiple-dose, double-blind, double-dummy, parallel, randomized, placebo and active controlled study of pharmacokinetics of Diractin® as well as safety and efficacy for muscle soreness from exercise.
- Trial name
- NCT00745771
- Testing
- Diractin
- Where
- Germany
- Volunteers
- 168 people, healthy volunteers welcome
- Sponsor
- IDEA AG
Muscle Spasticity
Retrospective Study of Patients With Spasticity in the Spanish Population
This is a retrospective study of patients with spasticity in the Spanish population.
- Trial name
- NCT01383681
- Testing
- No treatment
- Where
- Spain
- Volunteers
- 235 people
- Sponsor
- Allergan